京都大学 恩田佳幸 Ther Adv Hematol.2022 Jun 24;13:20406207221104584.

Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and
carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: A multicenter retrospective analysis

https://pubmed.ncbi.nlm.nih.gov/35785245/